Karyopharm Therapeutics Inc (NAS:KPTI)
$ 0.93 -0.0427 (-4.39%) Market Cap: 115.89 Mil Enterprise Value: 143.75 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Karyopharm Therapeutics Inc at JMP Securities Life Science Conference Transcript

Jun 19, 2019 / 03:30PM GMT
Release Date Price: $5.94 (+0.51%)
Unidentified Participant

(Audio in progress) Therapeutics and presenting is going to be Ian Karp, Vice President of Investor Relations and Public Relations.

Ian Karp
Karyopharm Therapeutics Inc. - VP of Investor & Public Relations

Thanks for joining me today. My name is Ian Karp; I head Investor Relations and Public Relations for Karyopharm. I will be making some forward-looking statements today, so please view our presentation on Karyopharm.com and you can read about those risks.

So, for those that are perhaps fairly new to Karyopharm, let me first start by just giving a brief overview of the Company to set the stage for some of the data that I will share. So, Karyopharm is actually an oncology focused company based in Newton, Massachusetts. We were actually founded about 10 years ago now and the Company is really focused on a technology surrounding the nucleus of cancer cells.

And this is a -- we are a leader in this space and this is a mechanism that has brought [us flexibility] across numerous genotypes. All the programs that I'll talk about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot